KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Payables (2016 - 2025)

Pfizer (PFE) has disclosed Payables for 17 consecutive years, with $7.7 billion as the latest value for Q4 2025.

  • Quarterly Payables fell 4.77% to $7.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.7 billion through Dec 2025, down 4.77% year-over-year, with the annual reading at $7.7 billion for FY2025, 4.77% down from the prior year.
  • Payables for Q4 2025 was $7.7 billion at Pfizer, up from $5.0 billion in the prior quarter.
  • The five-year high for Payables was $9.1 billion in Q4 2022, with the low at $4.1 billion in Q2 2021.
  • Average Payables over 5 years is $6.9 billion, with a median of $7.2 billion recorded in 2021.
  • The sharpest move saw Payables surged 35.48% in 2022, then crashed 37.29% in 2023.
  • Over 5 years, Payables stood at $7.8 billion in 2021, then increased by 16.42% to $9.1 billion in 2022, then decreased by 0.33% to $9.1 billion in 2023, then dropped by 11.14% to $8.1 billion in 2024, then decreased by 4.77% to $7.7 billion in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $7.7 billion, $5.0 billion, and $7.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.